Grégory Lambert

Dr. Grégory Lambert

TargEDys
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
MGMarie Galmiche
Marie Galmiche
PDPierre Déchelotte
Pierre Déchelotte
Grégory LambertGrégory Lambert
Grégory Lambert
MTMarie Pierre Tavolacci
Marie Pierre Tavolacci

14 March 2012 in Clinical Oral Investigations
Verified
Journal Article
Open access
PDF file
GKGilles Koubi
Gilles Koubi
PCPierre Colon
Pierre Colon
JFJean-Claude Franquin
Jean-Claude Franquin
AHAline Hartmann
Aline Hartmann
GRGilles Richard
Gilles Richard
Grégory LambertGrégory Lambert
Grégory Lambert
Objectives A multicentric randomized, 3-year prospective study was conducted to determine for how long Biodentine, a new biocompatible dentine substitute, can remain as a posterior restoration. Materials and methods First, Biodentine was compared to the composite Z100®, to evaluate whether and for how long it could be used as a posterior restoration according to selected United States Public Health Service (USPHS)’ criteria (mean ± SD). Second, when abrasion occurred, Biodentine was evaluated as a dentine substitute combined with Z100®. Results A total of 397 cases were included. This interim analysis was conducted on 212 cases that were seen for the 1-year recall. On the day of restoration placement, both materials obtained good scores for material handling, anatomic form (0.12 ± 0.33), marginal adaptation (0.01 ± 0.10) and interproximal contact (0.11 ± 0.39). During the follow-up, both materials scored well in surface roughness (≤1) without secondary decay and post-operative pain. Biodentine kept acceptable surface properties regarding anatomic form score (≤1), marginal adaptation score (≤2) and interproximal contact score (≤1) for up to 6 months after placement. Resistance to marginal discoloration was superior with Biodentine compared to Z100®. When Biodentine was retained as a dentine substitute after pulp vitality control, it was covered systematically with the composite Z100®. This procedure yielded restorations that were clinically sound and symptom free. Conclusions Biodentine is able to restore posterior teeth for up to 6 months. When subsequently covered with Z100®, it is a convenient, efficient and well tolerated dentine substitute. Clinical relevance Biodentine as a dentine substitute can be used under a composite for posterior restorations.

1 March 2001 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Grégory LambertGrégory Lambert
Grégory Lambert
EFElias Fattal
Elias Fattal
PCPatrick Couvreur
Patrick Couvreur

1 June 2000 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
Grégory LambertGrégory Lambert
Grégory Lambert
EFElias Fattal
Elias Fattal
HPHuguette Pinto-Alphandary
Huguette Pinto-Alphandary
AGAnnette Gulik
Annette Gulik
PCPatrick Couvreur
Patrick Couvreur

1 January 2014 in Journal of Biomechanics
Verified
Journal Article
Closed access
VMVincent Mathieu
Vincent Mathieu
RVRomain Vayron
Romain Vayron
GRGilles Richard
Gilles Richard
Grégory LambertGrégory Lambert
Grégory Lambert
SNSalah Naili
Salah Naili
GHGuillaume Haiat
Guillaume Haiat

1 December 2004 in Journal of Drug Targeting
Verified
Journal Article
Closed access
LRLaura Rabinovich-Guilatt
Laura Rabinovich-Guilatt
PCPatrick Couvreur
Patrick Couvreur
Grégory LambertGrégory Lambert
Grégory Lambert
CDCatherine Dubernet
Catherine Dubernet
Despite extensive research in the field, the major problem in the ocular drug delivery domain still is rapid precorneal drug loss and poor corneal permeability. One of the approaches recently developed is the drug incorporation into cationic submicronic vectors which exploit the negative charges present at the corneal surface for increased residence time and penetration. This review will focus on the formulation of three main representative cationic colloids developed for ophthalmic delivery: liposomes, emulsions and nanoparticles (NP). Parameters such as choice of the vector type and size, nature of the cationic molecule, pH and ionic strength of the external phase and characteristics of the encapsulated drug will be discussed with accent on the relevance of the positive charge.